Mirum’s Maralixibat for Alagille Syndrome Wins FDA Approval

Mirum Pharmaceuticals said the U.S. FDA approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome.

• Livmarli, a minimally absorbed ileal bile acid transporter inhibitor, is the first and only FDA-approved medication in this rare liver disease, the company said
• Livmarli is now available for prescribing
• Mirum shares are halted

To view the source of this information, click here

To contact the reporter on this story:
Hari Govind in San Francisco at hgovind@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2021 Bloomberg L.P. All rights reserved. Used with ...